R M Ara

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. doi request reprint Estimating health state utility values for joint health conditions: a conceptual review and critique of the current evidence
    Roberta Ara
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK
    Med Decis Making 33:139-53. 2013
  2. doi request reprint Using health state utility values in models exploring the cost-effectiveness of health technologies
    Roberta Ara
    The University of Sheffield, Sheffield, UK
    Value Health 15:971-4. 2012
  3. doi request reprint Principles of health economic evaluations of lipid-lowering strategies
    Roberta Ara
    The University of Sheffield, Sheffield, UK
    Curr Opin Lipidol 23:271-81. 2012
  4. doi request reprint Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods
    Roberta Ara
    Health Economics and Decision Science, ScHARR, The University of Sheffield, Sheffield, UK
    Med Care 50:452-9. 2012
  5. doi request reprint Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    R Ara
    School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK
    Eur J Prev Cardiol 19:474-83. 2012
  6. doi request reprint Estimating health state utility values for comorbid health conditions using SF-6D data
    Roberta Ara
    Health Economics and Decision Science, ScHARR, The University of Sheffield, Sheffield, UK
    Value Health 14:740-5. 2011
  7. doi request reprint Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available
    Roberta Ara
    The University of Sheffield, Sheffield, UK
    Value Health 14:539-45. 2011
  8. doi request reprint Populating an economic model with health state utility values: moving toward better practice
    Roberta Ara
    University of Shefield, Shefield, UK
    Value Health 13:509-18. 2010
  9. doi request reprint Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective
    Roberta Ara
    School of Health and Related Research, University of Sheffield, Regent Court, Sheffield S1 4DA, UK
    Expert Rev Pharmacoecon Outcomes Res 9:423-33. 2009
  10. doi request reprint Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model
    Roberta Ara
    Health Economics and Decision Science, ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK
    Am J Cardiovasc Drugs 8:419-27. 2008

Detail Information

Publications19

  1. doi request reprint Estimating health state utility values for joint health conditions: a conceptual review and critique of the current evidence
    Roberta Ara
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK
    Med Decis Making 33:139-53. 2013
    ..The methods can produce very different results, and there is currently no consensus on the most appropriate technique...
  2. doi request reprint Using health state utility values in models exploring the cost-effectiveness of health technologies
    Roberta Ara
    The University of Sheffield, Sheffield, UK
    Value Health 15:971-4. 2012
    ..Inconsistencies in the methodologies used will produce discrepancies in results, undermining policy decisions informed by cost per quality-adjusted life-years...
  3. doi request reprint Principles of health economic evaluations of lipid-lowering strategies
    Roberta Ara
    The University of Sheffield, Sheffield, UK
    Curr Opin Lipidol 23:271-81. 2012
    ..Decision makers need to be provided with a clear understanding of the key sources of evidence and how they are used in the DAM to make an informed judgement on the quality and appropriateness of the results generated...
  4. doi request reprint Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods
    Roberta Ara
    Health Economics and Decision Science, ScHARR, The University of Sheffield, Sheffield, UK
    Med Care 50:452-9. 2012
    ..There is currently no consensus on the most appropriate method to estimate health state utility values (HSUVs) for comorbid health conditions...
  5. doi request reprint Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    R Ara
    School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK
    Eur J Prev Cardiol 19:474-83. 2012
    ....
  6. doi request reprint Estimating health state utility values for comorbid health conditions using SF-6D data
    Roberta Ara
    Health Economics and Decision Science, ScHARR, The University of Sheffield, Sheffield, UK
    Value Health 14:740-5. 2011
    ..The methods used can produce very different results and there is currently no consensus on which is the most appropriate approach...
  7. doi request reprint Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available
    Roberta Ara
    The University of Sheffield, Sheffield, UK
    Value Health 14:539-45. 2011
    ....
  8. doi request reprint Populating an economic model with health state utility values: moving toward better practice
    Roberta Ara
    University of Shefield, Shefield, UK
    Value Health 13:509-18. 2010
    ..Despite this, there is no guidance on the preferred techniques and little research describing the effect on cost per quality adjusted life-year (QALY) results when using the different methods...
  9. doi request reprint Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective
    Roberta Ara
    School of Health and Related Research, University of Sheffield, Regent Court, Sheffield S1 4DA, UK
    Expert Rev Pharmacoecon Outcomes Res 9:423-33. 2009
    ..Simvastatin 80 mg/day should not be considered an alternative owing to an adverse safety profile and limited additional benefits...
  10. doi request reprint Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model
    Roberta Ara
    Health Economics and Decision Science, ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK
    Am J Cardiovasc Drugs 8:419-27. 2008
    ..To evaluate the cost effectiveness of long-term ezetimibe monotherapy in patients with established cardiovascular disease (CVD) who do not tolerate statins or in whom they are contraindicated...
  11. doi request reprint Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data regis
    Roberta Ara
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom
    Clin Ther 30:1508-23. 2008
    ..Ezetimibe has been reported to improve lipid control in patients with established cardiovascular disease (CVD)...
  12. doi request reprint Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available
    Roberta Ara
    Health Economics and Decision Science, The University of Sheffield, Sheffield, Yorkshire, UK
    Value Health 12:346-53. 2009
    ..The objective is to derive an algorithm to predict a cohort preference-based short form-6D (short form-6D) score using the eight mean health dimension scores from the short form-36 (SF-36) when patient level data are not available...
  13. doi request reprint Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available)
    Roberta Ara
    The University of Sheffield, Sheffield, UK
    Value Health 11:1131-43. 2008
    ..The objective of the study was to derive a method to predict a mean cohort EQ-5D preference-based index score using published mean statistics of the eight dimension scores describing the SF-36 health profile...
  14. ncbi request reprint The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit
    R M Ara
    Health Economics and Decision Science, ScHARR, University of Sheffield, 30 Regent Court, Sheffield S1 4DA, UK
    Rheumatology (Oxford) 47:68-71. 2008
    ..To explore the direct healthcare resources associated with ankylosing spondylitis (AS) in the UK. A secondary objective was to establish if resources, and thus healthcare costs, vary by disease severity...
  15. ncbi request reprint The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries
    R Ara
    School of Health and Related Research, The University of Sheffield, Sheffield, UK
    Obes Rev 8:363-71. 2007
    ....
  16. ncbi request reprint The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK
    R M Ara
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Regent Court, 40 Regent Street, Sheffield S1 4DA, UK
    Rheumatology (Oxford) 46:1338-44. 2007
    ..To examine the costs and benefits associated with long-term etanercept (ETN) treatment in patients with severe ankylosing spondylitis (AS) in the UK in accordance with the BSR guidelines...
  17. doi request reprint Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials
    A Pandor
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK
    J Intern Med 265:568-80. 2009
    ..To study the evidence on the efficacy and safety of ezetimibe monotherapy for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia...
  18. ncbi request reprint Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany
    Alan Brennan
    School of Health and Related Research, The University of Sheffield, Sheffield, UK
    Eur J Health Econ 7:276-84. 2006
    ..The CUA results are within the range generally accepted as cost effective and should be viewed as conservative when generalizing to settings offering standard non-pharmacological treatment...
  19. ncbi request reprint An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists
    Nick J Bansback
    Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK
    Drugs 65:473-96. 2005
    ....